Novo Nordisk A/S: FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity

Novo Nordisk A/S: FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity

Novo Nordisk A/S: FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity

BAGSVAERD, Denmark, May 20, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 11 September 2014 to discuss the New Drug Application (NDA) for liraglutide 3 mg for the treatment of obesity. The NDA was submitted to the FDA on 20 December 2013.

For further information


  Media:
  Mike Rulis                         +45 4442 3573      [email protected]
  Ken Inchausti (US)             +1 609 514 8316    [email protected]
  Investors:
  Kasper Roseeuw Poulsen    +45 3079 4303      [email protected]
  Jannick Lindegaard Denholt  +45 3079 8519      [email protected]
  Lars Borup Jacobsen           +45 3075 3479      [email protected]
  Daniel Bohsen                      +45 3079 6376      [email protected]
  Frank Daniel Mersebach (US)    +1 609 235 8567    [email protected]

Company announcement No 35 / 2014

Company announcement No 35 / 2014 http://hugin.info/2013/R/1787460/613749.pdf

HUG#1787460

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.